Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HepeX-B vs HBIg for HBV Prophylaxis in Liver Transplant
NCT00228592Phase 2Terminated
- Sponsor
- Merck & Co.
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of XTL-001 in hepatitis B (HBV), sponsored by Merck & Co.. Status: terminated.
02
Drugs
XTL-001
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00228592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00228592.